Press Release

Cognitive science company, Cogstate Ltd (ASX.CGS) and Clinical Ink, the
leading provider of eSource and patient engagement technologies, today
announced they have formalized their long-standing relationship with a
strategic alliance that delivers enhanced tablet-based
neuropsychological assessments for CNS clinical trials. The alliance
combines, in a single solution, the scientific and adult learning
expertise provided by Cogstate with the market-leading eSource data
capture platform from Clinical Ink.

“Our goal is to transform the entire rater experience with
process-enabling technologies that lead to better assessments, so a
partnership with the eSource pioneers at Clinical Ink was the clear
choice for advancing that objective”, commented Cogstate CEO, Brad
O’Connor. “This is one solution from two market leaders, so it is very
much aligned to the ‘best-of-breed’ approach that many sponsors are
taking for their outsourcing strategies; particularly in the area of CNS
where signal detection is so challenging and endpoint quality assurance
is so critical.”

“The benefits of eSource for CNS research are dramatic,” stated Ed
Seguine, CEO, Clinical Ink. “Combining Cogstate’s therapeutic expertise
with our SureSource® platform, which directly captures data
in the moment during the patient visit, promises to improve protocol
execution. Researchers can focus more attention on the patient and the
ratings when workflow and scoring are automated. This is an incredible
time for CNS research and Clinical Ink is delighted to partner with a
therapeutic leader like Cogstate on this advancement.”

This joint solution delivers important advantages to sponsors seeking to
transcend traditional paper-and-pencil assessment scales in their
clinical trials, including:

Same day access to quality source data and documents for central
monitoring by Cogstate’s network of local expert advisors (LEADs),
with custom flagging algorithms designed by clinical scientists for
rapid identification of rater variance

Rater training that reaches beyond the investigator meeting and
eLearning platforms by elegantly incorporating rater guidance directly
into the rating scale instrument used during the patient visit for
more accurate, standardized administration

Key Learnings from a recent multi-site study will be presented in a
live educational webinar, taking place
November 9th at 11:00 a.m. EST.

About Cogstate

Cogstate Ltd (ASX:CGS) is a leading cognitive science company dedicated
to simplifying the measurement of cognition in clinical trials, academic
research and healthcare. Cogstate provides expert support for
traditional neuropsychological and functional assessments to drive
higher quality measures, and commercializes rapid, reliable and highly
sensitive computerized cognitive tests. Cogstate customers include the
world’s leading biopharmaceutical companies; military and elite sporting
organizations; physicians and patients; renowned academic institutions
and public-private partnerships.

Founded in 2007, Clinical Ink® is transforming clinical
development with innovative eSource and patient engagement technologies
that make clinical research easier for sites, sponsors and patients.
Clinical Ink’s SureSource® platform directly captures eSource
data and documents from both patients and sites while improving protocol
execution and data quality. Clinical Ink maintains offices in Cambridge,
MA, Winston-Salem, NC, and Philadelphia, PA. Find more at www.clinicalink.com.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.